181 related articles for article (PubMed ID: 8903000)
1. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins.
Liu CZ; Hur BT; Huang TF
Thromb Haemost; 1996 Oct; 76(4):585-91. PubMed ID: 8903000
[TBL] [Abstract][Full Text] [Related]
2. Analysis of human platelet glycoprotein IIb-IIIa by fluorescein isothiocyanate-conjugated disintegrins with flow cytometry.
Liu CZ; Wang YW; Shen MC; Huang TF
Thromb Haemost; 1994 Dec; 72(6):919-25. PubMed ID: 7740464
[TBL] [Abstract][Full Text] [Related]
3. Crotavirin, a potent platelet aggregation inhibitor purified from the venom of the snake Crotalus viridis.
Liu CZ; Peng HC; Huang TF
Toxicon; 1995 Oct; 33(10):1289-98. PubMed ID: 8599180
[TBL] [Abstract][Full Text] [Related]
4. Blockade of glycoprotein IIb/IIIa by crotavirin, a member of disintegrins, prevents platelet from activation and aggregation by Staphylococcus aureus bacteria.
Liu CZ; Huang HY; Tsai PJ; Shih MH
Thromb Res; 2005; 116(2):145-55. PubMed ID: 15907530
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein specifically binds glycoprotein IIb/IIIa: a flow cytometric method for ligand-receptor interaction.
Tetik S; Uras F; Ekşioğlu-Demiralp E; Turay Yardimci K
Clin Appl Thromb Hemost; 2008 Apr; 14(2):210-9. PubMed ID: 18160616
[TBL] [Abstract][Full Text] [Related]
6. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
7. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor.
Coller BS; Peerschke EI; Seligsohn U; Scudder LE; Nurden AT; Rosa JP
J Lab Clin Med; 1986 Apr; 107(4):384-92. PubMed ID: 2420911
[TBL] [Abstract][Full Text] [Related]
8. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
9. A defined peptide that inhibits the formation of the glycoprotein IIb and IIIa complex.
Chiang TM; Zhu J
Thromb Res; 2005; 115(6):503-8. PubMed ID: 15792682
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry.
Faraday N; Goldschmidt-Clermont P; Dise K; Bray PF
J Lab Clin Med; 1994 May; 123(5):728-40. PubMed ID: 7515093
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa.
Christopoulos C; Mackie I; Lahiri A; Machin S
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):729-37. PubMed ID: 8292722
[TBL] [Abstract][Full Text] [Related]
12. A new short chain RGD-containing disintegrin, accutin, inhibits the common pathway of human platelet aggregation.
Yeh CH; Peng HC; Yih JB; Huang TF
Biochim Biophys Acta; 1998 Nov; 1425(3):493-504. PubMed ID: 9838213
[TBL] [Abstract][Full Text] [Related]
13. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.
Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y
Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
15. Shear stress-induced binding of von Willebrand factor to platelets.
Konstantopoulos K; Chow TW; Turner NA; Hellums JD; Moake JL
Biorheology; 1997; 34(1):57-71. PubMed ID: 9176590
[TBL] [Abstract][Full Text] [Related]
16. Studies of fibrinogen binding to platelets by flow cytometry: an improved method for studies of platelet activation.
Lindahl TL; Festin R; Larsson A
Thromb Haemost; 1992 Aug; 68(2):221-5. PubMed ID: 1412170
[TBL] [Abstract][Full Text] [Related]
17. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of the platelet surface area and surface density of glycoprotein IIb-IIIa of unactivated human platelets of various sizes.
Leytin V; Shapiro H; Novikov I; Radnay J
Biochem Biophys Res Commun; 1996 Sep; 226(1):94-100. PubMed ID: 8806597
[TBL] [Abstract][Full Text] [Related]
20. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
